A detailed history of Dunhill Financial, LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Dunhill Financial, LLC holds 32 shares of CRSP stock, worth $1,303. This represents 0.0% of its overall portfolio holdings.

Number of Shares
32
Previous 32 -0.0%
Holding current value
$1,303
Previous $1.73 Million 13.02%
% of portfolio
0.0%
Previous 0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 12, 2024

BUY
$38.62 - $72.18 $1,235 - $2,309
32 New
32 $2 Million

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.18B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Dunhill Financial, LLC Portfolio

Follow Dunhill Financial, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dunhill Financial, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dunhill Financial, LLC with notifications on news.